Deborah A Pearson1, Cynthia W Santos1, Michael G Aman2, L Eugene Arnold2, David M Lane3, Katherine A Loveland1, Rosleen Mansour1, Anthony R Ward1, Charles D Casat4, Susan Jerger5, Russell J Schachar6, Oscar G Bukstein7, Lynne A Cleveland1. 1. Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA. 2. Nisonger Center, Ohio State University, Columbus, Ohio, USA. 3. Department of Psychological Sciences and Department of Statistics, Rice University, Houston, Texas, USA. 4. Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA. 5. School of Behavioral and Brain Sciences, The University of Texas at Dallas, Dallas, Texas, USA. 6. The Hospital for Sick Children, Toronto, Canada. 7. Boston Children's Hospital, Boston, Massachusetts, USA.
Abstract
Objective: To examine the effectiveness of four doses of psychostimulant medication, combining extended-release methylphenidate (ER-MPH) in the morning with immediate-release MPH (IR-MPH) in the afternoon, on cognitive task performance. Method: The sample comprised 24 children (19 boys and 5 girls) who met the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revision (DSM-IV-TR) criteria for an autism spectrum disorder (ASD) on the Autism Diagnostic Interview-R and the Autism Diagnostic Observation Schedule, and had significant symptoms of attention-deficit/hyperactivity disorder (ADHD). This sample consisted of elementary school-age, community-based children (mean chronological age = 8.8 years, SD = 1.7; mean intelligence quotient = 85; SD = 16.8). Effects of placebo and three dose levels of ER-MPH (containing 0.21, 0.35, and 0.48 mg/kg equivalent of IR-MPH) on cognitive task performance were compared using a within-subject, crossover, placebo-controlled design. Each of the four MPH dosing regimens (placebo, low-dose MPH, medium-dose MPH, and high-dose MPH) was administered for 1 week; the dosing order was counterbalanced across children. Results: MPH treatment was associated with significant performance gains on cognitive tasks tapping sustained attention, selective attention, and impulsivity/inhibition. Dose/response was generally linear in the dose range studied, with no evidence of deterioration in performance at higher MPH doses in the dose range studied. Conclusion: The results of this study suggest that MPH formulations are associated with significant improvements on cognitive task performance in children with ASD and ADHD.
RCT Entities:
Objective: To examine the effectiveness of four doses of psychostimulant medication, combining extended-release methylphenidate (ER-MPH) in the morning with immediate-release MPH (IR-MPH) in the afternoon, on cognitive task performance. Method: The sample comprised 24 children (19 boys and 5 girls) who met the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revision (DSM-IV-TR) criteria for an autism spectrum disorder (ASD) on the Autism Diagnostic Interview-R and the Autism Diagnostic Observation Schedule, and had significant symptoms of attention-deficit/hyperactivity disorder (ADHD). This sample consisted of elementary school-age, community-based children (mean chronological age = 8.8 years, SD = 1.7; mean intelligence quotient = 85; SD = 16.8). Effects of placebo and three dose levels of ER-MPH (containing 0.21, 0.35, and 0.48 mg/kg equivalent of IR-MPH) on cognitive task performance were compared using a within-subject, crossover, placebo-controlled design. Each of the four MPH dosing regimens (placebo, low-dose MPH, medium-dose MPH, and high-dose MPH) was administered for 1 week; the dosing order was counterbalanced across children. Results: MPH treatment was associated with significant performance gains on cognitive tasks tapping sustained attention, selective attention, and impulsivity/inhibition. Dose/response was generally linear in the dose range studied, with no evidence of deterioration in performance at higher MPH doses in the dose range studied. Conclusion: The results of this study suggest that MPH formulations are associated with significant improvements on cognitive task performance in children with ASD and ADHD.
Authors: Margaret H Sibley; William E Pelham; Brooke S G Molina; Elizabeth M Gnagy; James G Waxmonsky; Daniel A Waschbusch; Karen J Derefinko; Brian T Wymbs; Allison C Garefino; Dara E Babinski; Aparajita B Kuriyan Journal: J Consult Clin Psychol Date: 2012-07-09
Authors: Deborah A Pearson; Katherine A Loveland; David Lachar; David M Lane; Stacy L Reddoch; Rosleen Mansour; Lynne A Cleveland Journal: Child Neuropsychol Date: 2006-08 Impact factor: 2.500
Authors: Deborah A Pearson; David M Lane; Cynthia W Santos; Charles D Casat; Susan W Jerger; Katherine A Loveland; Laura P Faria; Rosleen Mansour; Jill A Henderson; Christa D Payne; John D Roache; David Lachar; Lynne A Cleveland Journal: J Am Acad Child Adolesc Psychiatry Date: 2004-06 Impact factor: 8.829
Authors: Rachel R Lee; Anthony R Ward; David M Lane; Michael G Aman; Katherine A Loveland; Rosleen Mansour; Deborah A Pearson Journal: J Autism Dev Disord Date: 2021-01-30